Cargando…
Treatment of multiple system atrophy using intravenous immunoglobulin
BACKGROUND: Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia. Disease-modifying therapies are unavailable. Activation of microglia and production of toxic cytokines suggest...
Autores principales: | Novak, Peter, Williams, Arlene, Ravin, Paula, Zurkiya, Omar, Abduljalil, Amir, Novak, Vera |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551813/ https://www.ncbi.nlm.nih.gov/pubmed/23116538 http://dx.doi.org/10.1186/1471-2377-12-131 |
Ejemplares similares
-
Adhesion Molecules, Altered Vasoreactivity, and Brain Atrophy in Type 2 Diabetes
por: Novak, Vera, et al.
Publicado: (2011) -
Multi-Scale Glycemic Variability: A Link to Gray Matter Atrophy and Cognitive Decline in Type 2 Diabetes
por: Cui, Xingran, et al.
Publicado: (2014) -
Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study
por: Novak, Peter, et al.
Publicado: (2019) -
The Relationship Between Brain Volume and Walking Outcomes in Older Adults With and Without Diabetic Peripheral Neuropathy
por: Manor, Brad, et al.
Publicado: (2012) -
Enhancement of Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes
por: Novak, Vera, et al.
Publicado: (2014)